Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will release its third quarter 2021 financial results on November 2, 2021, post-market. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can join the call by dialing (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 9545716. Pulmonx is known for its minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients worldwide.

Positive

• Pulmonx received FDA pre-market approval for the Zephyr Valve as a 'breakthrough device'.
• The Zephyr Valve is commercially available in more than 25 countries.
• Over 100,000 valves have been used to treat patients.

Negative

• None.

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday, November 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 9545716. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

What is the date for Pulmonx's Q3 2021 financial results release?

Pulmonx will release its Q3 2021 financial results on November 2, 2021.

At what time will the Pulmonx earnings conference call take place?

The conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET.

How can I listen to the Pulmonx conference call?

Investors can call (833) 614-1518 for domestic or (270) 823-1072 for international access, using Conference ID: 9545716.

What is the significance of the Zephyr Valve for Pulmonx?

The Zephyr Valve, approved as a 'breakthrough device', is key to Pulmonx's offerings and has been used in over 25,000 patients.